Presentation ACC 2017 A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Presenter: Magnus Ohman March 27, 2017
Presentation ACC 2017 EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism Presenter: Jeff Weitz March 20, 2017
News Conference News ACC 2017 VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery L.A. McKeown March 19, 2017
News Conference News ACC 2017 Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe Todd Neale March 18, 2017
News Conference News ACC 2017 Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE L.A. McKeown March 18, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017